Univariate analysis of the risk factors associated with 5-year OS and EFS
| Characteristics . | Training cohort . | Validation cohort . | ||||||
|---|---|---|---|---|---|---|---|---|
| OS, % . | P . | EFS, % . | P . | OS, % . | P . | EFS, % . | P . | |
| Sex | .55 | .08 | .8 | .81 | ||||
| Male | 51.4 | 31.8 | 51.7 | 44.8 | ||||
| Female | 56.7 | 38.1 | 57.1 | 48.6 | ||||
| Age, y | .07 | .64 | .53 | .10 | ||||
| <70 | 33.8 | 21.4 | 31.6 | 31.6 | ||||
| ≥70 | 32.0 | 22.3 | 22.2 | 44.4 | ||||
| ECOG performance status | 1.00 | .32 | .12 | .11 | ||||
| 0 or 1 | 34.7 | 12.0 | 31.1 | 36.6 | ||||
| 2 | 29.1 | 10.0 | 10.5 | 21.1 | ||||
| Ann Arbor stage | .50 | .81 | .07 | .07 | ||||
| I or II | 53.0 | 33.3 | 50.0 | 25.0 | ||||
| III or IV | 45.6 | 21.9 | 42.3 | 46.2 | ||||
| Extranodal sites, n | .76 | .11 | .48 | .11 | ||||
| 0 | 21.7 | 19.2 | 40.9 | 32.0 | ||||
| 1 | 19.2 | 8.3 | 16.7 | 12.9 | ||||
| Bone marrow involvement | .63 | .50 | .52 | .21 | ||||
| Yes | 40.0 | 20.0 | 50.0 | 38.2 | ||||
| No | 33.2 | 10.5 | 60.0 | 56.7 | ||||
| B symptoms | .67 | 1.00 | <.01 | <.01 | ||||
| Yes | 36.7 | 16.7 | 31.0 | 27.6 | ||||
| No | 33.5 | 10.8 | 74.3 | 62.9 | ||||
| LDH | .76 | .08 | .03 | <.01 | ||||
| Normal | 15.6 | 13.3 | 42.7 | 40.9 | ||||
| >Normal | 12.2 | 9.8 | 16.3 | 17.2 | ||||
| MH | <.01 | <.01 | .01 | .02 | ||||
| Low | 34.9 | 20.0 | 46.9 | 31.3 | ||||
| High | 9.3 | 7.0 | 18.8 | 15.6 | ||||
| Characteristics . | Training cohort . | Validation cohort . | ||||||
|---|---|---|---|---|---|---|---|---|
| OS, % . | P . | EFS, % . | P . | OS, % . | P . | EFS, % . | P . | |
| Sex | .55 | .08 | .8 | .81 | ||||
| Male | 51.4 | 31.8 | 51.7 | 44.8 | ||||
| Female | 56.7 | 38.1 | 57.1 | 48.6 | ||||
| Age, y | .07 | .64 | .53 | .10 | ||||
| <70 | 33.8 | 21.4 | 31.6 | 31.6 | ||||
| ≥70 | 32.0 | 22.3 | 22.2 | 44.4 | ||||
| ECOG performance status | 1.00 | .32 | .12 | .11 | ||||
| 0 or 1 | 34.7 | 12.0 | 31.1 | 36.6 | ||||
| 2 | 29.1 | 10.0 | 10.5 | 21.1 | ||||
| Ann Arbor stage | .50 | .81 | .07 | .07 | ||||
| I or II | 53.0 | 33.3 | 50.0 | 25.0 | ||||
| III or IV | 45.6 | 21.9 | 42.3 | 46.2 | ||||
| Extranodal sites, n | .76 | .11 | .48 | .11 | ||||
| 0 | 21.7 | 19.2 | 40.9 | 32.0 | ||||
| 1 | 19.2 | 8.3 | 16.7 | 12.9 | ||||
| Bone marrow involvement | .63 | .50 | .52 | .21 | ||||
| Yes | 40.0 | 20.0 | 50.0 | 38.2 | ||||
| No | 33.2 | 10.5 | 60.0 | 56.7 | ||||
| B symptoms | .67 | 1.00 | <.01 | <.01 | ||||
| Yes | 36.7 | 16.7 | 31.0 | 27.6 | ||||
| No | 33.5 | 10.8 | 74.3 | 62.9 | ||||
| LDH | .76 | .08 | .03 | <.01 | ||||
| Normal | 15.6 | 13.3 | 42.7 | 40.9 | ||||
| >Normal | 12.2 | 9.8 | 16.3 | 17.2 | ||||
| MH | <.01 | <.01 | .01 | .02 | ||||
| Low | 34.9 | 20.0 | 46.9 | 31.3 | ||||
| High | 9.3 | 7.0 | 18.8 | 15.6 | ||||